Eli Lilly and (LLY) stock
LLY · Eli Lilly and Company · NYSE
What is the latest news on LLY stock?
LLY fell 0.24% to $1348.20 on Nov 20, 2026. No LLY story in the last two days; the most recent is below.
VANCOUVER, BC, Nov. 18, 2026 /CNW/ -- Stock Preachers News Commentary - Major indices were mixed as of midday Wednesday, with the Dow down sharply and the Nasdaq Composite little changed to higher on the day even as all four benchmarks remain lower on the week. Gold, silver and crude oil all fell sharply on the day and the week, while the CBOE Volatility Index eased on the day but jumped on the week. Against that backdrop, cybersecurity and semiconductor-linked names drew attention, led by Cisco's latest quarterly results. Active Companies from around the markets with current developments this week include: Cisco (NASDAQ:CSCO), Alimentation Couche-Tard Inc. (TSX:ATD), Eli Lilly and Company (
All LLY newsWho owns the most LLY stock?
Lilly Endowment Inc was the largest reported holder of LLY at the end of Q2 2026, with 90,376,978 shares worth $108.4 billion. Next came BlackRock, Inc. ($81.0 billion) and Vanguard Capital Management LLC ($64.2 billion). In all, 4,619 institutions reported $943.6 billion of LLY in their 13F filings.
All LLY fund holdersAre insiders buying or selling LLY?
Insiders are selling. In the last 90 days 1 insider sold $7.0 million of LLY in trades reported on Form 4. The latest: Anat Hakim sold $7.0 million, reported on Nov 3, 2026.
LLY insider tradesFinancial highlights
Full financials- Revenue, TTM
- $86.46B
- Revenue growth
- +45.5%
- Net income, TTM
- $27.58B
- Net margin
- 31.9%
- Cash
- $4.88B
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- PRGold, Silver and Crude Slide Hard as Volatility Jumps on the WeekVANCOUVER, BC, Nov. 18, 2026 /CNW/ -- Stock Preachers News Commentary - Major indices were mixed as of midday Wednesday, with the Dow down sharply and the Nasdaq Composite little changed to higher on the day even as all four benchmarks remain lower on the week. Gold, silver and crude oil all fell sharply on the day and the week, while the CBOE Volatility Index eased on the day but jumped on the week. Against that backdrop, cybersecurity and semiconductor-linked names drew attention, led by Cisco's latest quarterly results. Active Companies from around the markets with current developments this week include: Cisco (NASDAQ:CSCO), Alimentation Couche-Tard Inc. (TSX:ATD), Eli Lilly and Company (
- INSIDERDirector Jamere Jackson was granted 168 shares, increasing direct ownership by 2% to 9,861 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Jon R Moeller was granted 168 shares, increasing direct ownership by 55% to 473 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector William G Kaelin Jr was granted 168 shares, increasing direct ownership by 0.76% to 22,139 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Kimberly H Johnson was granted 168 shares, increasing direct ownership by 5% to 3,452 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Carolyn R Bertozzi was granted 178 shares, increasing direct ownership by 9% to 2,178 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Katherine Baicker was granted 168 shares, increasing direct ownership by 0.71% to 23,815 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Mary Lynne Hedley was granted 168 shares, increasing direct ownership by 7% to 2,430 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Gabrielle Sulzberger was granted 171 shares, increasing direct ownership by 6% to 3,188 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Juan R Luciano was granted 179 shares, increasing direct ownership by 1% to 17,148 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector J Erik Fyrwald was granted 175 shares, increasing direct ownership by 0.23% to 75,719 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Ralph Alvarez was granted 176 shares, increasing direct ownership by 0.32% to 56,025 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- FDAFDA Approval for RETEVMO issued to ELI LILLY AND COSubmission status for ELI LILLY AND CO's drug RETEVMO (SUPPL-9) with active ingredient SELPERCATINIB has changed to 'Approval' on 11/16/2026. Application Category: NDA, Application Number: 218160, Application Classification: Efficacy
- FDAFDA Approval for RETEVMO issued to ELI LILLY AND COSubmission status for ELI LILLY AND CO's drug RETEVMO (SUPPL-18) with active ingredient SELPERCATINIB has changed to 'Approval' on 11/16/2026. Application Category: NDA, Application Number: 213246, Application Classification: Efficacy
- PRStocks Carry Weekly Gains Into a Wall of Chart Resistance as Volatility CoolsVANCOUVER, BC, Nov. 17, 2026 /CNW/ -- Stock Preachers News Commentary - Wall Street heads into the new week with solid weekly gains behind it, even after Friday's pullback. The Dow Jones Industrial Average, S&P 500, Nasdaq Composite and Russell 2000 all closed the week higher, while the VIX and VXN volatility gauges fell sharply from a week earlier, even as both ticked up on Friday. Gold, silver, copper and WTI crude all lost ground on the week, while natural gas rose and the 10-year Treasury yield climbed. Active Companies from around the markets with current developments this week include: Alimentation Couche-Tard Inc. (TSX:ATD) and Eli Lilly and Company (NYSE:LLY).
- PRLilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scalePhase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetesResults from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesityPeople reported Foundayo was simple and easy to use in a new real-world evidence study, while patient-reported outcomes showed that participants treated with eloralintide reported reductions in food noise, food cravings and alcohol consumptionINDIANAPOLIS, Nov. 14, 2026 /PRNewswire/ -- Eli Lilly an
- PRWeekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields ClimbVANCOUVER, BC, Nov. 13, 2026 /CNW/ -- Stock Preachers News Commentary - Wall Street closed out a volatile week with every major index still higher versus last Friday, even after a broad Friday retreat. The Nasdaq Composite led decliners with a 1.24% drop on the session, while the S&P 500 fell 0.75% and the Dow slipped 0.14%. For the week, the S&P 500 gained 2.15%, the Nasdaq rose 1.92% and the Dow added 1.83%, as chip-driven strength carried the market even as Friday gave back some ground heading into the weekend. Active Companies from around the markets with current developments this week include: Eli Lilly and Company (NYSE:LLY), vVardis (NYSE:VVVV), NVIDIA Corporation (NASDAQ:NVDA), Cater
- PRLilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020Facility will manufacture injectable medicines, including retatrutide Site will create 850 high-wage jobs and 2,000 construction jobsINDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today broke ground on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley. The site is one of 10 new U.S. manufacturing sites announced since 2020 and one of four among them dedicated to injectable medicines and devices. Part of the company's $50 billion push to expand medicine production in the U.S., the Lehigh Valley site will add capacity for the next generation of obesity treatments, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon t
- PRNasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek RallyVANCOUVER, BC, Nov. 11, 2026 /CNW/ -- Stock Preachers News Commentary - Stocks staged a broad midweek advance, with the Nasdaq Composite climbing 2.06% on the session and 4.08% for the week to 25,583.42, while the S&P 500 added 1.4% on the day for a 3.38% weekly gain and the Dow rose 2.05% over the same stretch. The Russell 2000 gained 3.27% for the week. Volatility eased sharply, with the VIX down 2.10 points and the VXN down 5.45 points from last week, even as one closely watched chipmaker found itself sidelined by headlines rather than earnings. Active Companies from around the markets with current developments this week include: Enbridge (TSX:ENB), Sunlife (TSX:SLF), RBC (TSX:RY), Lilly
- PRNew Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesityNearly three times as many patients taking Taltz and Zepbound achieved ≥50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA studyImprovements in disease activity at one year follow statistically superior outcomes observed with Taltz and Zepbound vs. Taltz alone at Week 36 primary endpointDetailed data were featured as an oral presentation at ACR Convergence 2026 and simultaneously published in Arthritis & Rheumatology INDIANAPOLIS, Nov. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label
- INSIDEREVP & President, LLY Int'l Jonsson Patrik gifted 704 shares, decreasing direct ownership by 1% to 53,443 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- PRLife doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waitingAfter years of thinking she should be able to manage her weight on her own, Leanne shares how a conversation with her doctor led her to Foundayo, and why she encourages others to talk with their healthcare providersINDIANAPOLIS, Nov. 10, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and partner Leanne Morgan today announced the launch of Life Doesn't Slow Down, a new campaign for Lilly's Foundayo™ (orforglipron), a once-daily prescription GLP-1 pill proven to help adults with obesity, or some adults with overweight who also have weight-related medical problems, lose weight and keep it off, along with a reduced-calorie diet and increased physical activity. Leanne has built a career on
- PRIndices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays ElevatedVANCOUVER, BC, Nov. 9, 2026 /CNW/ -- Stock Preachers News Commentary - Wall Street opens a new week nursing bruises from a rough stretch that sent every major index lower, with the Nasdaq Composite off 3.37% and the S&P 500 down 2.68% from the prior week's reference close. The CBOE Volatility Index settled at 23.5, still up 2.35 points on the week even after easing 2.14 points on the day, as traders weigh whether recent lows mark a floor or just a pause before further declines. Active Companies from around the markets with current developments this week include: Enbridge Inc. (TSX:ENB), Amgen (NASDAQ:AMGN), Thomson Reuters (TSX:TRI), Sun Life Financial Inc. (TSX:SLF), and Eli Lilly and Compa
- PRLilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight lossIn adults with moderate-to-severe OSA and obesity or overweight, Foundayo reduced breathing interruptions during sleep by up to an average of 44%, with up to 32% of participants achieving remission or mild disease Foundayo also reduced sleep apnea-specific hypoxic burden by up to an average of 55.9%, improving oxygen levels during sleepLilly plans to submit Foundayo to the U.S. FDA for moderate-to-severe obstructive sleep apnea by the end of 2026INDIANAPOLIS, Nov. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo (orforglipro
- PRGabelli Releases Agenda for 8th Annual Healthcare SymposiumPALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the Paley Center for Media in New York. The symposium will bring together leading companies and organizations from across the healthcare ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals. This symposium features three panel discussions with senior leaders from across the healthcare industry, including providers, biopharmaceutical companies, distributors, payers, and healthcare technology companies. Discussions will cover the pace of oncol
LLY rankings
- Other50(56%)
- Insider31(35%)
- Dividends3(3%)
- Earnings2(2%)
- SEC Filings2(2%)
- Analyst1(1%)
Our reporting on LLY
- Venrock buys $644,711 of Lycia stock at $25.78, 43% above the $18 IPO price and 14% below the first-day closeAnalysis · Nov 1, 2026 · 7 min read

- Stifel cuts Acumen to Hold at $1.00 after sabirnetug fails Phase 2 and the stock falls about 86% to 89% intradayAnalysis · Oct 31, 2026 · 6 min read

- West Pharmaceutical Q3 sales rise 8.7% to $874.5 million as HVP Components adds $76.8 million, more than the whole $70.0 million gainAnalysis · Oct 29, 2026 · 6 min read

- Lilly Q3 revenue rises 39% to $24.4 billion, but about $900 million of one-time benefits lift growth from roughly 34%Analysis · Oct 29, 2026 · 6 min read

Eli Lilly and Company (LLY) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 47 wire items for LLY, including 21 insider trades, 20 press releases and news items and 3 dividend updates. The most recent was published Nov 19, 2026.
LLY FAQ
9 questionsWhat does Eli Lilly and Company do?
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer...What is LLY revenue?
Eli Lilly and Company (LLY) reported $86.46B of revenue for the twelve months ended Sep 30, 2026. That is up 45.5% from the year before. Revenue for fiscal 2025 was $65.18B.Is LLY profitable?
Yes. Eli Lilly and Company earned $27.58B in net income for the twelve months ended Sep 30, 2026, a net margin of 31.9%.How much cash and debt does LLY have?
Eli Lilly and Company reported $4.88B in cash and cash equivalents and $49.50B of debt on its most recent balance sheet in SEC filings.Where does LLY stock trade?
Eli Lilly and Company (LLY) is listed on NYSE.What sector and industry is LLY in?
Eli Lilly and Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about LLY?
Across the last 8 analyst actions on Eli Lilly and Company, there were 2 upgrades and 1 downgrade. The most recent action was from Berenberg: Buy with a $1400.00 price target on 2026-09-15. Recent price targets range from $850.00 to $1400.00.What companies are similar to LLY?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), NVO (Novo Nordisk A/S), AMGN (Amgen Inc.). Compare LLY side-by-side with any of them on Quantisnow.How can I track LLY on Quantisnow?
Quantisnow aggregates Eli Lilly and Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LLY to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change